NCTId,BriefTitle,OverallStatus,StudyType,Phases,Conditions,LeadSponsorName,StartDate,StudyFirstPostDate,LastUpdatePostDate,Timestamp
NCT05670730,Study of AOC 1044 in Healthy Adult Volunteers and Participants with Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,"PHASE1, PHASE2","Duchenne Muscular Dystrophy, Exon 44","Avidity Biosciences, Inc.",2022-11-09,2023-01-04,2024-09-23,2024-10-29T07:19:40.910850
NCT02994030,Biomarker for Duchenne Muscular Dystrophy,COMPLETED,OBSERVATIONAL,,"Increased Lordosis/Scoliosis, Hyporeflexia, Duchenne Muscular Dystrophy, Red-Green Color Blindness, Lordosis, Scoliosis, Muscular Atrophy, Muscular Weakness",CENTOGENE GmbH Rostock,2018-08-20,2016-12-15,2022-03-24,2024-10-29T07:19:40.910850
NCT00758225,"Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)",COMPLETED,INTERVENTIONAL,PHASE2,Duchenne Muscular Dystrophy,Santhera Pharmaceuticals,2008-09,2008-09-25,2011-06-01,2024-10-29T07:19:40.910850
